Enanta announces October 22 RSV data presentation for Enanta Pharmaceuticals stock
Published on 10/20/2026 at 20:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRSV program and reporting date
- Enanta announced an October 22, 2026 presentation of zelicapavir RSV data on October 13, 2026.
- Fiscal third-quarter revenue was USD 14.36 million versus USD 16.76 million consensus.
- Enanta Pharmaceuticals stock costs EUR 10.45 at Lang & Schwarz on October 20, 2026 at 7:59 p.m. CEST.
- The next estimated earnings date is November 16, 2026.
Enanta Pharmaceuticals (ISIN US29251M1062) will present clinical data for its zelicapavir RSV program on October 22, 2026, after announcing the presentation on October 13, 2026. The company said the Phase 2 poster will cover symptom resolution, hospitalization and viral load in high-risk adults, according to Enanta Pharmaceuticals. At Lang & Schwarz, the stock was trading at EUR 10.45 on October 20, 2026 at 7:59 p.m. CEST.
RSV data arrives October 22
The scheduled presentation is the nearest company-specific event for investors. The poster is titled Zelicapavir Decreases Time to Complete RSV Symptom Resolution, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of High-Risk Adults, with presentation details set for October 22, 2026 at 12:15 p.m. ET. The release names Christopher E. Harris as presenter and places the session in Poster Hall B-C.
How does the price compare?
Enanta's Nasdaq quote was USD 11.76 on October 20, 2026 at 2:04 p.m. EDT. The same market record places the 52-week range at USD 10.20 to USD 17.15, leaving the quote USD 1.56 above the low and USD 5.39 below the high. Trading volume stood at 92,316 shares at that timestamp.
Valuation and reporting dates
Enanta's market capitalization was USD 342.5 million and its trailing price-to-earnings ratio was negative 4.88 on October 20, 2026. The company reported fiscal third-quarter revenue of USD 14.36 million for the period ended June 30, 2026, below the USD 16.76 million consensus estimate, while diluted earnings per share were a loss of USD 0.67, according to the standardized financial record and MarketBeat.
The next estimated earnings date is November 16, 2026, with a conference call scheduled for 4:00 p.m. ET. MarketBeat lists expected revenue of USD 14.62 million and a consensus loss of USD 0.7240 per share for fiscal fourth-quarter 2026.
Comparison with peers
Enanta Pharmaceuticals: 0.00 percent change stated for the euro quote, negative 4.88 price-to-earnings ratio, USD 342.5 million market capitalization. Gilead Sciences (Nasdaq, USD): up 1.93 percent, negative 58.44 price-to-earnings ratio, USD 193.5 billion market capitalization. Vir Biotechnology (Nasdaq, USD): up 5.63 percent, negative 5.80 price-to-earnings ratio, USD 1.8 billion market capitalization. The peer figures are dated October 20, 2026.
Enanta stock in euros
The German-market quote gives investors a euro view while the primary listing remains on Nasdaq. The current Lang & Schwarz price was EUR 10.45 on October 20, 2026 at 7:59 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals market report
- Company: Enanta Pharmaceuticals, Inc.
- ISIN: US29251M1062
- Ticker: ENTA
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 7:59 p.m. CEST): EUR 10.45
- Market capitalization: USD 342.5 million (as of October 20, 2026)
- 52-week range: USD 10.20-17.15 (as of October 20, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 16, 2026
Market context: Market report S&P 500.
